All News

T2T.RA_.jpg

Measureable Benefits to Treat-to-Target Management in RA

Jack Cush, MD

Desai and colleagues have published that when a learning collaborative group focused on a treat‐to‐target approach was compared to usual care, a modest but significant impact on implementation, treatment changes and patient outcomes in RA patients managed with a treat‐to‐target approach was seen.

Read Article
rwcsmtg.jpeg

RWCS Highlights - Day 3

Rachel Tate, DO

Day 3 report from the 2021 RWCS meeting in Maui (and virtually) includes pearls from the PsA 2020 Year in Review; fact vs. fiction on evidence based medicine: diet and rheumatic diseases; hot topics in allergy/immunology; and pediatric rheumatology highlights.

Read Article
620 RA patients from Nordic biologics registers started a non-TNFi as 1steverr bDMARD but later switched to a 2nd bDMARD (ABA 86, RTX 40, TCZ 67 TNFi 427). Retention was 70% @ 6 mos & 50% @12 mos. 30-40% on 2nd bDMARD reached LDAS or remission https://t.co/u8BQn0rYca

Links:

Dr. John Cush RheumNow ( View Tweet)

Compared with no statin use; statin use in RA pts is assoc w/ 28% lower mortality risk. Population study of 19,614 RA pts w/ incident statin use, compared 1,883 statin users vs 1,883 nonusers. All-cause mortality was lower (HR 0.72;0.56-0.91) w/ statins https://t.co/onMlWoVdPL

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Measureable Benefits to Treat-to-Target Management in RA https://t.co/iAvLWJGTXp https://t.co/NfNj3MWznI

Links:

Dr. John Cush RheumNow ( View Tweet)
Pooled analysis of 16 observational RA registries (27 583 patients) shows that seropositivity was associated with better remission, LDAS and withdrawal rates for RTX and ABA, but not TNF inhibitors. https://t.co/aNphJpB7JB

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - RA or Not? Lessons from the clinic. Enough serology, but not enough joints - when does it become RA? https://t.co/akklOklPee

Links:

Dr. John Cush RheumNow ( View Tweet)

We are three weeks out from RheumNow Live. Are you planning on attending? https://t.co/vJlU0Z3Q3x

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Measurable Benefits withTreat-to-Target Management in RA https://t.co/iAvLWJGTXp https://t.co/XNtGhoWs5I

Links:

Dr. John Cush RheumNow ( View Tweet)
We are excited to share that Roy Fleischmann will be leading a discussion on future therapy in RA at RheumnNow Live next month. Sign up today to attend in person or virtually. https://t.co/vJlU0Z3Q3x https://t.co/uN1MrzWZA9

Links:

Dr. John Cush RheumNow ( View Tweet)
Cohort analysis of 12351 RA patients from CPRD registry - finds RA on both glucorticoids & PPI have a greater risk OP fractures (adj HR: 1.60, 95% CI: 1.35 to 1.89) vs non-use. Higher than the Fx Risk with either oral GC or PPI use alone (adj HR 1.2). https://t.co/oPMnJoHCjX https://t.co/eW7rpVeHa4

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort study shows the risk of RA was lower in T2DM/diabetes (aHR 0.73; 95% CI 0.67–0.79) vs without T2DM. This risk was lost in when statins were not used (aHR 0.89; 0.69–1.14). Statins (in T2DM) had a protective effect against RA onset https://t.co/CfMJIuGOXI

Links:

Dr. John Cush RheumNow ( View Tweet)

We are excited to announce that Jeff Sparks ( @jeffsparks) will be leading a discussion on ILD in RA at RheumNow Live this March. Register to attend today. https://t.co/uwxOVh142F https://t.co/bnittqkhKQ

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinics- The Sawtooth Steroid Taper Sawtooth Steroid Taper Surgery Rules for DMARDs & Biologics RA & DVT Traveling to Medical Meetings during COVID Hemoptysis and SLE When to do Genetic Testing in Febrile Patients https://t.co/dZLqGUyizG https://t.co/PYsH7K6ByB

Links:

Dr. John Cush RheumNow ( View Tweet)
Analysis of incident #RA in UK Clinical Practice registry shows recent prednisone >=7.5mg/d is assoc w/ hypertension in RA. In 17760 RA pts, 42% were Rx steroids; recent GC yielded a 17% increase in HTN (HR 1.17); only >7.5mg/D implicated https://t.co/qUKs2oZZUV https://t.co/pWmD4nKs6U

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - RA and DVT Counseling Patients on JAKs and Thrombotic Risk https://t.co/efQGtkrxHF https://t.co/mfhjZYMlUC

Links:

Dr. John Cush RheumNow ( View Tweet)
RWCS Highlights - Day 4 from Dr. Rachel Tate ( @uptotate) -Novel Therapies Year in Review (RA, SLE, OA) -Novel concepts in Pediatric Rheumatology -TeleRheumatology Update: Post-COVID, Pre-?? https://t.co/JoTV25suxD https://t.co/Id19zgRT37

Links:

Dr. John Cush RheumNow ( View Tweet)
30 #RA pts treated w/ tofacitinib x 12 mos w/ signif improvement in DAS28, CRP, & HAQ and attenuation of further bone loss, as measured by significantly increased osteocalcin, OPG, and vitamin D3, with decreased CTX levels correlating w/ DXA results https://t.co/RSXL38cJvs

Links:

Dr. John Cush RheumNow ( View Tweet)

🔥 Increased baseline prevalence and 40% higher risk of developing #Multimorbidity after #RA incidence/index vs general population @CrowsonCindy @JohnDavisIII #MayoClinicRheumatology ⁦@jrheum⁩ ⁦@NIAMSFunding⁩ ⁦@NIH⁩ https://t.co/8GolTowAGm

Links:

Elena MyasoedovaMD MyasoedovaElena ( View Tweet)

Prospective study of 162 early RA pts looked at Xrays (baseline & 5 yrs). RF & ESR predicted erosion & JSN progression; CCP predicted erosions; Smoking & high DAS28 > 5.1 predicted progression of erosions. Obesity negatively predicted JSN progression https://t.co/fue121hHVw

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×